TNF Pharmaceuticals IncNASDAQ:TNFA
- LAST PRICE1.4000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.0500/ 1
- Ask / Lots1.6500/ 4
- Open / Previous Close--- / 1.4000
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TNFA |
|---|---|---|
| 09:32 ET | 1433 | 1.39 |
| 09:37 ET | 600 | 1.39 |
| 09:53 ET | 364 | 1.4 |
| 10:13 ET | 600 | 1.37 |
| 10:20 ET | 287 | 1.37 |
| 10:22 ET | 200 | 1.36 |
| 10:26 ET | 100 | 1.36 |
| 10:33 ET | 1530 | 1.37 |
| 10:58 ET | 800 | 1.37 |
| 11:02 ET | 950 | 1.355 |
| 11:48 ET | 100 | 1.36 |
| 11:56 ET | 100 | 1.3648 |
| 11:59 ET | 400 | 1.39 |
| 12:17 ET | 699 | 1.4 |
| 12:26 ET | 424 | 1.37 |
| 12:35 ET | 300 | 1.4 |
| 12:53 ET | 300 | 1.42 |
| 01:00 ET | 5900 | 1.425 |
| 01:04 ET | 600 | 1.41 |
| 01:31 ET | 209 | 1.44 |
| 01:33 ET | 2078 | 1.435 |
| 01:44 ET | 11060 | 1.44 |
| 01:54 ET | 10031 | 1.47 |
| 02:12 ET | 390 | 1.46 |
| 02:23 ET | 450 | 1.46 |
| 02:36 ET | 468 | 1.47 |
| 02:45 ET | 2300 | 1.3919 |
| 02:57 ET | 1849 | 1.49 |
| 03:28 ET | 145 | 1.48 |
| 03:33 ET | 638 | 1.5 |
| 03:37 ET | 654 | 1.49 |
| 03:39 ET | 200 | 1.45 |
| 03:42 ET | 200 | 1.45 |
| 03:44 ET | 400 | 1.425 |
| 03:46 ET | 737 | 1.4 |
| 03:51 ET | 1000 | 1.4364 |
| 04:00 ET | 338 | 1.4 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
TNF Pharmaceuticals Inc | 3.7M | -0.3x | --- |
Lixte Biotechnology Holdings Inc | 3.7M | -1.2x | --- |
Channel Therapeutics Corp | 3.8M | -0.4x | --- |
Artelo Biosciences Inc | 3.6M | -0.4x | --- |
Qualigen Therapeutics Inc | 3.6M | -0.1x | --- |
Tharimmune Inc | 3.8M | -0.1x | --- |
Company Information
MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. The Company’s MYMD-1 is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. It also shows potential as an anti-fibrotic and anti-prolific therapeutic. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. Supera-CBD is a synthetic, preclinical cannabidiol derivative that has been demonstrated to effectively target cannabinoid type 2 (CB2) receptors. Supera-CBD binds to and inhibits opioid receptors, comparing it side by side with plant-based cannabidiol (CBD).
Contact Information
- Headquarters
- 855 N. Wolfe Street, Suite 601BALTIMORE, MD, United States 21205
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Joshua Silverman
- President, Director, Chief Medical Officer
- Mitchell Glass
- Interim Chief Financial Officer
- Ian Rhodes
- Executive Vice President - Operations, General Counsel, Chief Legal Officer
- Paul Rivard
- Director
- Christopher Schreiber
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 2.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.20 |
EPS | $-5.53 |
Book Value | $11.17 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
